These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 23891189)

  • 1. XIAP and P-glycoprotein co-expression is related to imatinib resistance in chronic myeloid leukemia cells.
    Silva KL; de Souza PS; Nestal de Moraes G; Moellmann-Coelho A; Vasconcelos Fda C; Maia RC
    Leuk Res; 2013 Oct; 37(10):1350-8. PubMed ID: 23891189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imatinib increases apoptosis index through modulation of survivin subcellular localization in the blast phase of CML cells.
    Bernardo PS; Reis FR; Maia RC
    Leuk Res; 2012 Dec; 36(12):1510-6. PubMed ID: 22975581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P-glycoprotein and survivin simultaneously regulate vincristine-induced apoptosis in chronic myeloid leukemia cells.
    Souza PS; Vasconcelos FC; De Souza Reis FR; Nestal De Moraes G; Maia RC
    Int J Oncol; 2011 Oct; 39(4):925-33. PubMed ID: 21720708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphorylated Crkl reduction levels are associated with the lowest P-glycoprotein activity levels in cells from chronic myeloid leukemia patients.
    Vasconcelos FC; Nestal de Moraes G; Moellmann-Coelho A; Maia RC
    Leuk Res; 2013 Dec; 37(12):1711-8. PubMed ID: 24210993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(-) population to imatinib.
    Airiau K; Mahon FX; Josselin M; Jeanneteau M; Turcq B; Belloc F
    Exp Hematol; 2012 May; 40(5):367-78.e2. PubMed ID: 22240609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variation of MDR proteins expression and activity levels according to clinical status and evolution of CML patients.
    Vasconcelos FC; Silva KL; Souza PS; Silva LF; Moellmann-Coelho A; Klumb CE; Maia RC
    Cytometry B Clin Cytom; 2011 May; 80(3):158-66. PubMed ID: 21520403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of STAT5 confers imatinib resistance on leukemic cells through the transcription of TERT and MDR1.
    Yamada O; Ozaki K; Furukawa T; Machida M; Wang YH; Motoji T; Mitsuishi T; Akiyama M; Yamada H; Kawauchi K; Matsuoka R
    Cell Signal; 2011 Jul; 23(7):1119-27. PubMed ID: 21356308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous targeting of P-gp and XIAP with siRNAs increases sensitivity of P-gp overexpressing CML cells to imatinib.
    Seca H; Lima RT; Guimarães JE; Helena Vasconcelos M
    Hematology; 2011 Mar; 16(2):100-8. PubMed ID: 21418741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate.
    Illmer T; Schaich M; Platzbecker U; Freiberg-Richter J; Oelschlägel U; von Bonin M; Pursche S; Bergemann T; Ehninger G; Schleyer E
    Leukemia; 2004 Mar; 18(3):401-8. PubMed ID: 14724652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of bortezomib on reverse multidrug resistance and XIAP expression in imatinib-resistant primary cells of chronic myeloid leukemia in blastic crisis].
    Zhao J; Ma LM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Aug; 21(4):899-904. PubMed ID: 23998582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imatinib resistance in multidrug-resistant K562 human leukemic cells.
    Assef Y; Rubio F; Coló G; del Mónaco S; Costas MA; Kotsias BA
    Leuk Res; 2009 May; 33(5):710-6. PubMed ID: 18977528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Divalproex sodium enhances the anti-leukemic effects of imatinib in chronic myeloid leukemia cells partly through SIRT1.
    Wang W; Zhang J; Li Y; Yang X; He Y; Li T; Ren F; Zhang J; Lin R
    Cancer Lett; 2015 Jan; 356(2 Pt B):791-9. PubMed ID: 25449787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-cell analysis of K562 cells: an imatinib-resistant subpopulation is adherent and has upregulated expression of BCR-ABL mRNA and protein.
    Karimiani EG; Marriage F; Merritt AJ; Burthem J; Byers RJ; Day PJ
    Exp Hematol; 2014 Mar; 42(3):183-191.e5. PubMed ID: 24269846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistent activation of the Fyn/ERK kinase signaling axis mediates imatinib resistance in chronic myelogenous leukemia cells through upregulation of intracellular SPARC.
    Fenouille N; Puissant A; Dufies M; Robert G; Jacquel A; Ohanna M; Deckert M; Pasquet JM; Mahon FX; Cassuto JP; Raynaud S; Tartare-Deckert S; Auberger P
    Cancer Res; 2010 Dec; 70(23):9659-70. PubMed ID: 21098700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CUEDC2 sensitizes chronic myeloid leukemic cells to imatinib treatment.
    Zhang H; Chang G; Wang J; Lin Y; Ma L; Pang T
    Leuk Res; 2013 Nov; 37(11):1583-91. PubMed ID: 24125838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MYC antagonizes the differentiation induced by imatinib in chronic myeloid leukemia cells through downregulation of p27(KIP1.).
    Gómez-Casares MT; García-Alegria E; López-Jorge CE; Ferrándiz N; Blanco R; Alvarez S; Vaqué JP; Bretones G; Caraballo JM; Sánchez-Bailón P; Delgado MD; Martín-Perez J; Cigudosa JC; León J
    Oncogene; 2013 Apr; 32(17):2239-46. PubMed ID: 22710719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imatinib-resistant K562 cells are more sensitive to celecoxib, a selective COX-2 inhibitor: role of COX-2 and MDR-1.
    Arunasree KM; Roy KR; Anilkumar K; Aparna A; Reddy GV; Reddanna P
    Leuk Res; 2008 Jun; 32(6):855-64. PubMed ID: 18083230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cleavage of BCR-ABL transcripts at the T315I point mutation by DNAzyme promotes apoptotic cell death in imatinib-resistant BCR-ABL leukemic cells.
    Kim JE; Yoon S; Choi BR; Kim KP; Cho YH; Jung W; Kim DW; Oh S; Kim DE
    Leukemia; 2013 Aug; 27(8):1650-8. PubMed ID: 23434731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imatinib and bortezomib induce the expression and distribution of anaphase-promoting complex adaptor protein Cdh1 in blast crisis of chronic myeloid leukemia.
    Wang Q; Zhou HS; Huang KK; Jiang XJ; Wu FQ; Cao R; Yin CX; Liao LB; Zheng ZX; He H; Lin R; Yi ZS; Xu D; Yang M; Meng FY
    Int J Oncol; 2012 Feb; 40(2):418-26. PubMed ID: 22002244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models.
    Mahon FX; Belloc F; Lagarde V; Chollet C; Moreau-Gaudry F; Reiffers J; Goldman JM; Melo JV
    Blood; 2003 Mar; 101(6):2368-73. PubMed ID: 12609962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.